Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves
inflammation from its inception to the emergence of complications. Targeting inflammatory …

The past decades have witnessed hyperthermia therapy (HTT) as an emerging strategy
against malignant tumors. Nanomaterial‐based photothermal therapy (PTT) and magnetic …

During the past recent years, various therapies emerged in the era of breast cancer. Breast
cancer is a heterogeneous disease in which genetic and environmental factors are involved …

The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor
sites accurately and properly activate complex immune responses. Herein, we design and …

Abstract SynergyFinder (https://synergyfinder. fimm. fi) is a stand-alone web-application for
interactive analysis and visualization of drug combination screening data. Since its first …

Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …

Checkpoint immunotherapies have been combined with other therapeutic modalities to
increase patient response rate and improve therapeutic outcome, which however …

CD8+ cytotoxic T lymphocytes (CTLs) are preferred immune cells for targeting cancer.
During cancer progression, CTLs encounter dysfunction and exhaustion due to …

Radiotherapy (RT) uses ionizing radiation to eradicate localized tumors and, in rare cases,
control tumors outside of the irradiated fields via stimulating an antitumor immune response …